Bremelanotide
Melanocortin Receptor Agonist | Sexual Dysfunction Treatment
DoseGear research brief
FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.
Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Bremelanotide, developed from melanocortin-analog research.
Sexual-function research and a defined approved sexual-desire indication through central melanocortin-receptor agonism.
Not reported for an attributable injectable-vial response window in the reviewed evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Female HSDD (FDA-approved) | 1.75mg | As needed, max 1 dose/24hr | SubQ |
| Male Erectile Dysfunction | 1-2mg | As needed, 45-60min before activity | SubQ |
| Female Arousal Disorder | 0.75-1.25mg | As needed, max 1 dose/24hr | SubQ |
| Low Starting Dose | 0.5mg | Test dose for tolerance assessment | SubQ |
Reference cycle
Use as needed for sexual enhancement
Reference storage
Refrigerate at 2-8°C, use reconstituted solution within 30 days
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)
Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile Dysfunction
The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal Women
Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
